Potential new treatment option in ultra-rare, life-threatening, primarily pediatric disease with no approved therapies Lausanne (Switzerland), March 7, 2023 -- AB2 Bio Ltd., a biotechnology company ...

Find the latest ABN AMRO Bank N.V. (AB2.F) stock quote, history, news and other vital information to help you with your stock trading and investing.

Japan’s Nippon Shinyaku is continuing to scoop up the international rights to some intriguing drugs, this time penning a $686 million biobucks deal for AB2 Bio’s late-stage autoimmune disease therapy.

AB2 Bio, a Swiss clinical-stage biotech company developing therapies for the treatment of severe systemic autoinflammatory diseases, and WuXi Biologics agreed to collaborate to set up and accelerate ...

Swiss orphan biotech AB2 Bio Ltd. has completed enrollment in a pivotal phase III trial for its recombinant interleukin-18-binding protein drug tadekinig alfa for an inherited form of the ultra-rare ...

AB2 Bio has made an option and licencing agreement with Nippon Shinyaku, granting the latter the option to obtain exclusive ...

Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio's Tadekinig alfa to treat Primary Monogenic IL-18 driven Hyperinflammatory Syndrome in patients ...

The AB2.4ON, AB2.4S and AB2.5GN arrive in Orange Neon, Silver and Green Neon respectively, with matte finishes and sharp headstocks all-round When you purchase through links on our site, we may earn ...